“Fed Proof” Your Bank Account with THESE 4 Simple Steps

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

Reid McCarthy Biography and Net Worth

Director of Annovis Bio

Mr. McCarthy is experienced in corporate financial management, operations and new venture development. He was CFO of Topaz Pharmaceuticals, Inc. until its sale in 2011 to Sanofi Pasteur. He also served as CFO of JJ Haines & Company, Inc. and provided consulting CFO services to several life sciences companies. He has been a founding executive of several venture capital-backed companies which were successfully sold.

What is Reid McCarthy's net worth?: The estimated net worth of Reid McCarthy is at least $43,295.86 as of August 19th, 2021. Mr. McCarthy owns 6,829 shares of Annovis Bio stock worth more than $43,296 as of December 4th. This net worth estimate does not reflect any other investments that Mr. McCarthy may own. Learn More about Reid McCarthy's net worth.
How do I contact Reid McCarthy?: The corporate mailing address for Mr. McCarthy and other Annovis Bio executives is 1055 Westlakes Drive Suite 300, Berwyn PA, 19312. Annovis Bio can also be reached via phone at 610-727-3913 and via email at [email protected]. Learn More on Reid McCarthy's contact information.
Has Reid McCarthy been buying or selling shares of Annovis Bio?: Reid McCarthy has not been actively trading shares of Annovis Bio during the past quarter. Most recently, on Thursday, August 19th, Reid Mccarthy bought 500 shares of Annovis Bio stock. The stock was acquired at an average cost of $37.61 per share, with a total value of $18,805.00. Following the completion of the transaction, the director now directly owns 6,829 shares of the company's stock, valued at $256,838.69. Learn More on Reid McCarthy's trading history.
Who are Annovis Bio's active insiders?: Annovis Bio's insider roster includes Claudine Bruck (Director), Maria-Luisa Maccecchini (CEO), and Reid McCarthy (Director). Learn More on Annovis Bio's active insiders.

Reid McCarthy Insider Trading History at Annovis Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/19/2021	Buy	500	$37.61	$18,805.00	6,829

Reid McCarthy Buying and Selling Activity at Annovis Bio

Annovis Bio Company Overview

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Today's Range

Now: $6.34

$6.34

$7.21

50 Day Range

MA: $8.08

$6.51

$9.88

2 Week Range

Now: $6.34

$4.53

$22.49

Volume

471,770 shs

Average Volume

217,290 shs

Market Capitalization

$87.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59

The Crypto Secret Wall Street Doesn’t Want You to Know

From Crypto 101 Media | Ad

The Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.

Click here to discover our #1 crypto for the market right now – poised for massive growth